Karyopharm Therapeutics Inc (OQ:KPTI)

Business Focus: Bio Therapeutic Drugs

Sep 23, 2019 09:19 am ET
CLASS ACTION UPDATE for MMM, KPTI, GTT and VRAY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Sep 23, 2019 08:45 am ET
MONDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Karyopharm Therapeutics Inc. (“Karyopharm” or “the Company”) (NASDAQ: KPTI) for violations of §§10(b) and 20(a) of the...
Sep 22, 2019 10:50 pm ET
KARYOPHARM 24 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS of Deadline in Class Action Lawsuit Against Karyopharm Therapeutics Inc. - KPTI
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with losses in excess of $100,000 that they have only until September 23, 2019 to file lead plaintiff applications in a...
Sep 21, 2019 10:00 am ET
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Karyopharm Therapeutics, Inc. (NASDAQ: KPTI) and Encourages Karyopharm Investors to Con
Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all investors that purchased Karyopharm, Inc. (NASDAQ: KPTI) securities between March 2, 2017 to February 22, 2019 (the “Class Period”). Investors have until September 23, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Sep 20, 2019 10:50 pm ET
KARYOPHARM 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit Against Karyopharm Therapeutics Inc. - KPTI
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with losses in excess of $100,000 that they have only until September 23, 2019 to file lead plaintiff applications in a securities class action lawsuit against Karyopharm Therapeutics Inc. (NasdaqGS: KPTI). Investor losses must relate to purchases of the Company’s shares between March 2, 2017 and February 22, 2019 or issued in connection with its April 2017 or May 2018 public offering. This action is pending in the United States Di
Sep 20, 2019 03:00 pm ET
INVESTOR ALERT - Karyopharm Therapeutics Inc. (KPTI) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders With Losses Exceeding $100K of Class Action and Lead Deadline: September 23, 2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Karyopharm Therapeutics Inc. (“Karyopharm”  or “the Company”) (NASDAQ:  KPTI) and certain of its officers, on behalf of...
Sep 20, 2019 01:00 pm ET
FINAL SEPT. 23 DEADLINE: GLOBALLY RECOGNIZED ROSEN LAW FIRM Reminds Karyopharm Therapeutics Inc. Investors of Important September 23rd Deadline in Securities Class Action – KPTI
Rosen Law Firm, a global investor rights law firm, reminds Karyopharm Therapeutics Inc. (NASDAQ: KPTI) investors who purchased securities: (i) from March 2, 2017 through February 22, 2019, inclusive (the “Class Period”); (ii) in or traceable to...
Sep 20, 2019 10:04 am ET
MONDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or “the Company”) (NASDAQ:
Sep 19, 2019 10:00 am ET
FINAL DEADLINE ALERT - Karyopharm Therapeutics Inc. (KPTI) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders With Losses Exceeding $100K of Class Action and Lead Deadline: September 23, 2019
NEW YORK, Sept. 19, 2019 /PRNewswire/ -- Attorney Advertising --Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Karyopharm Therapeutics Inc. ("Karyopharm"  or "the Company") (NASDAQ:  KPTI) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Karyopharm securities between March 2, 2017 and February 22, 2019, both dates inclusive. Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/kpti.  ...
Sep 19, 2019 09:46 am ET
SHAREHOLDER ALERT: LB KPTI EGBN MDP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Sep 18, 2019 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN) Class Period: 3/2/2015 - 7/17/2019Lead Plaintiff Motion Deadline: September...
Sep 18, 2019 08:21 pm ET
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Karyopharm Therapeutics, Inc. (NASDAQ: KPTI) and Encourages Karyopharm Investors to Con
NEW YORK, Sept. 18, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all investors that purchased Karyopharm, Inc. (NASDAQ: KPTI) securities between March 2, 2017 to February 22, 2019 (the "Class Period").  Investors have until September 23, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit....
Sep 17, 2019 07:44 pm ET
Pomerantz Law Firm Announces the Filing of a Class Action against Karyopharm Therapeutics Inc. and Certain Officers – KPTI
Pomerantz LLP announces that a class action lawsuit has been filed against Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI) and certain of its officers.   The class action, filed in United States District Court, for the...
Sep 17, 2019 09:58 am ET
CLASS ACTION UPDATE for NFLX, KPTI, GTT and EVH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Sep 16, 2019 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN)Class Period: 3/2/2015 -...
Sep 16, 2019 01:30 pm ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Karyopharm Therapeutics, Inc.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 23, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Karyopharm Therapeutics, Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI)...
Sep 16, 2019 10:30 am ET
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Karyopharm Therapeutics, Inc.
Law Offices of Howard G. Smith reminds investors of the upcoming September 23, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Karyopharm Therapeutics, Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI)...
Sep 16, 2019 08:50 am ET
7-DAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Karyopharm Therapeutics Inc. (“Karyopharm” or “the Company”) (NASDAQ: KPTI) for violations of §§10(b) and 20(a) of the...
Sep 16, 2019 07:00 am ET
Karyopharm Enters Into Royalty Agreement with Healthcare Royalty Partners for up to $150 Million
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced its entry into a royalty agreement with HealthCare Royalty Partners (HCR) for up to $150 million to support the ongoing development and...
Sep 13, 2019 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN) Class Period: 3/2/2015 - 7/17/2019Lead Plaintiff Motion Deadline: September...
Sep 13, 2019 06:30 pm ET
Karyopharm Announces XPOVIO™ (Selinexor) Presentations at the 17th International Myeloma Workshop
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that five abstracts highlighting clinical data for XPOVIO™ (selinexor) will be presented at the 17th International Myeloma Workshop (IMW) taking...
Sep 13, 2019 03:00 pm ET
Class Action Update - NFLX, KPTI & MNK - Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Sep 12, 2019 05:05 pm ET
ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Karyopharm Therapeutics Inc. Investors of Important September 23rd Deadline in Securities Class Action – KPTI
Rosen Law Firm, a global investor rights law firm, reminds Karyopharm Therapeutics Inc. (NASDAQ: KPTI) investors who purchased securities: (i) from March 2, 2017 through February 22, 2019, inclusive (the “Class Period”); (ii) in or traceable to...
Sep 12, 2019 02:44 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....
Sep 12, 2019 09:32 am ET
SHAREHOLDER ALERT: OMCL KPTI NTAP TXT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Sep 11, 2019 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN)Class Period: 3/2/2015 -...
Sep 11, 2019 09:24 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of RBGLY, KPTI, PS and TXT
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Sep 10, 2019 07:30 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Omnicell, Ideanomics, Eagle Bancorp, and Karyopharm and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Omnicell, Inc. (NASDAQ: OMCL), Ideanomics, Inc. (NASDAQ: IDEX), Eagle Bancorp,  Inc. (NASDAQ: EGBN), and Karyopharm...
Sep 10, 2019 04:30 pm ET
NATIONALLY RANKED ROSEN LAW FIRM Reminds Karyopharm Therapeutics Inc. Investors of Important September 23rd Deadline in Securities Class Action; ENCOURAGES INVESTORS WITH LOSSES IN EXCESS OF $100K TO
Rosen Law Firm, a global investor rights law firm, reminds Karyopharm Therapeutics Inc. (NASDAQ: KPTI) investors who purchased securities: (i) from March 2, 2017 through February 22, 2019, inclusive (the “Class Period”); (ii) in or traceable to...
Sep 10, 2019 11:01 am ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc.  To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI) of the September 23, 2019 deadline to seek the role of lead plaintiff in a federal...
Sep 10, 2019 09:38 am ET
CLASS ACTION UPDATE for OMCL, KPTI, CURLF and TWOU: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Sep 09, 2019 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN) Class Period: 3/2/2015 - 7/17/2019Lead Plaintiff Motion Deadline: September...
Sep 09, 2019 09:40 am ET
UPCOMING DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contac
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Karyopharm Therapeutics Inc. (“Karyopharm” or “the Company”) (NASDAQ: KPTI) for violations of §§10(b) and 20(a) of the...
Sep 06, 2019 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN)Class Period:...
Sep 06, 2019 09:27 am ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of KPTI, EGBN, MNK and CAH
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Sep 05, 2019 03:44 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....
Sep 05, 2019 10:10 am ET
SHAREHOLDER ALERT: INS KPTI EGBN VAL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Sep 04, 2019 11:00 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI) of the September 23, 2019 deadline to seek the role of lead plaintiff in a federal...
Sep 04, 2019 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN) Class Period: 3/2/2015 - 7/17/2019Lead Plaintiff Motion Deadline: September...
Sep 04, 2019 03:00 pm ET
NFLX, KPTI & MNK - Bronstein, Gewirtz & Grossman, LLC – Class Action Update
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Sep 04, 2019 09:33 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of INS, OMCL, KPTI and CAH
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Sep 03, 2019 10:30 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ideanomics, Eagle Bancorp, Karyopharm Therapeutics, and National General Holdings and Encourages Invest
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Ideanomics, Inc (NASDAQ: IDEX), Eagle Bancorp, Inc. (NASDAQ: EGBN), Karyopharm Therapeutics, Inc. (NASDAQ: KPTI), and National...
Sep 03, 2019 09:46 am ET
CLASS ACTION UPDATE for NFLX, KPTI, GVA and CVS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Sep 03, 2019 08:40 am ET
UPCOMING DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact t
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Karyopharm Therapeutics Inc. (“Karyopharm” or “the Company”) (NASDAQ: KPTI) for violations of §§10(b) and 20(a) of the...
Sep 03, 2019 07:00 am ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 39,000 shares of Karyopharm’s...
Sep 02, 2019 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN) Class Period: 3/2/2015...
Aug 30, 2019 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN) Class Period: 3/2/2015 - 7/17/2019Lead Plaintiff Motion Deadline: September...
Aug 30, 2019 03:00 pm ET
Karyopharm Therapeutics Inc. (KPTI), Mallinckrodt plc (MNK) & National General Holdings Corp. (NGHC) - Bronstein, Gewirtz & Grossman, LLC – Class Action Update
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Aug 29, 2019 01:29 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....
Aug 29, 2019 12:56 pm ET
ROSEN, A TOP RANKED LAW FIRM, Reminds Karyopharm Therapeutics Inc. Investors of Important September 23rd Deadline in Securities Class Action - KPTI
Rosen Law Firm, a global investor rights law firm, reminds Karyopharm Therapeutics Inc. (NASDAQ: KPTI) investors who purchased securities: (i) from March 2, 2017 through February 22, 2019, inclusive (the “Class Period”); (ii) in or traceable to...
Aug 29, 2019 11:28 am ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI) of the September 23, 2019 deadline to seek the role of lead plaintiff in a federal...
Aug 29, 2019 09:14 am ET
SHAREHOLDER ALERT: LB KPTI EVH VAL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Aug 28, 2019 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN) Class Period: 3/2/2015...
Aug 28, 2019 09:14 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of KPTI, JE, GTT and VAL
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Aug 28, 2019 07:00 am ET
Karyopharm to Participate in Upcoming Investor Conferences
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, announced today that the Company’s management team will participate in the following upcoming investor conferences:  The Baird 2019 Global Healthcare...
Aug 27, 2019 09:36 am ET
CLASS ACTION UPDATE for VNTR, KPTI, GTT and VAL: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Aug 27, 2019 08:00 am ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Karyopharm, L Brands, National General, and Mallinckrodt and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Karyopharm Therapeutics, Inc. (NASDAQ: KPTI), L Brands, Inc. (NYSE: LB), National General Holdings Corp. (NASDAQ: NGHC), and...
Aug 26, 2019 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN) Class Period: 3/2/2015 - 7/17/2019Lead Plaintiff Motion Deadline: September...
Aug 26, 2019 10:06 pm ET
Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against Karyopharm Therapeutics Inc. – KPTI
Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) from March 2, 2017 through February 22, 2019, inclusive (the “Class Period”). The lawsuit...
Aug 26, 2019 11:35 am ET
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Karyopharm Therapeutics Inc. (“Karyopharm” or “the Company”) (NASDAQ: KPTI) for violations of §§10(b) and 20(a) of the...
Aug 24, 2019 10:35 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
NEW YORK, Aug. 24, 2019 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ: KPTI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980....
Aug 24, 2019 10:35 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
NEW YORK, Aug. 24, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ: KPTI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980....
Aug 23, 2019 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN) Class Period: 3/2/2015...
Aug 23, 2019 03:00 pm ET
Karyopharm Therapeutics Inc. (KPTI), Mallinckrodt plc (MNK) & National General Holdings Corp. (NGHC) – Class Action Reminder – Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Aug 22, 2019 10:00 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FDX, CTST, KPTI and NGHC
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Aug 21, 2019 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN) Class Period: 3/2/2015 - 7/17/2019Lead Plaintiff Motion Deadline: September...
Aug 21, 2019 05:20 pm ET
Karyopharm Announces Publication of XPOVIO™ (Selinexor) Phase 2b STORM Study Results in The New England Journal of Medicine
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that the results of the Phase 2b STORM study evaluating XPOVIO™ (selinexor) in patients with heavily pretreated, triple class refractory...
Aug 21, 2019 03:47 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc.  To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI) of the September 23, 2019 deadline to seek the role of lead plaintiff in a federal...
Aug 20, 2019 03:49 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....
Aug 20, 2019 09:20 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Karyopharm Therapeutics Inc. (“Karyopharm” or “the Company”) (NASDAQ: KPTI) for violations of §§10(b) and 20(a) of the...
Aug 19, 2019 10:50 pm ET
Shareholder Alert by Former Louisiana Attorney General: KSF Reminds EGBN, KPTI, LB, NGHC Investors of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN) Class Period: 3/2/2015...
Aug 19, 2019 09:42 am ET
CLASS ACTION UPDATE for TEVA, FDX, NFLX and KPTI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Aug 18, 2019 07:30 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Eagle Bancorp, Karyopharm, L Brands, and National General and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Eagle Bancorp, Inc. (NASDAQ: EGBN), Karyopharm Therapeutics, Inc. (NASDAQ: KPTI), L Brands, Inc. (NYSE: LB), and National...
Aug 16, 2019 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN) Class Period: 3/2/2015 - 7/17/2019Lead Plaintiff Motion Deadline: September...
Aug 15, 2019 05:26 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....
Aug 15, 2019 09:29 am ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of KPTI, EGBN, CARB and CAH
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Aug 14, 2019 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN) Class Period:...
Aug 14, 2019 11:59 am ET
CLASS ACTION UPDATE for KPTI, NGHC and PS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Aug 13, 2019 09:49 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of NFLX, KPTI, NGHC and TWOU
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Aug 12, 2019 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN) Class Period: 3/2/2015 - 7/17/2019Lead Plaintiff Motion Deadline: September...
Aug 12, 2019 02:16 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI) of the September 23, 2019 deadline to seek the role of lead plaintiff in a federal...
Aug 12, 2019 01:20 pm ET
INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact th
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Karyopharm Therapeutics Inc. (“Karyopharm” or “the Company”) (NASDAQ: KPTI) for violations of §§10(b) and 20(a) of the...
Aug 12, 2019 08:54 am ET
CLASS ACTION UPDATE for INS, NFLX, KPTI and NGHC: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Aug 11, 2019 09:12 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Netflix, EQT, Eagle Bancorp, and Karyopharm and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Netflix, Inc. (NASDAQ: NFLX), EQT Corporation (NYSE: EQT), Eagle Bancorp, Inc. (NASDAQ: EGBN), and Karyopharm Therapeutics,...
Aug 09, 2019 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN) Class Period: 3/2/2015...
Aug 09, 2019 03:33 pm ET
ROSEN, A TOP RANKED LAW FIRM, Reminds Karyopharm Therapeutics Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm –
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) from March 2, 2017 through February 22, 2019, inclusive (the “Class Period”) of the important September 23, 2019 lead plaintiff deadline in the case. The lawsuit seeks to recover damages for Karyopharm investors under the federal securities laws.
Aug 09, 2019 03:26 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....
Aug 08, 2019 09:55 am ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BUD, CTST, OMCL and KPTI
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Aug 07, 2019 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN) Class Period: 3/2/2015 - 7/17/2019Lead Plaintiff Motion Deadline: September...
Aug 06, 2019 03:15 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI) of the September 23, 2019 deadline to seek the role of lead plaintiff in a federal...
Aug 06, 2019 09:37 am ET
SHAREHOLDER ALERT: DBD OMCL NFLX KPTI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Aug 06, 2019 07:00 am ET
Karyopharm Reports Second Quarter 2019 Financial Results and Highlights Recent Company Progress
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today reported financial results for the second quarter 2019.  In addition, Karyopharm highlighted select corporate milestones, including an update regarding...
Aug 05, 2019 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN) Class Period: 3/2/2015...
Aug 05, 2019 09:30 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against EQT Corporation, Eagle Bancorp, Karyopharm, and L Brands, Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of EQT Corporation, Eagle Bancorp, Inc., Karyopharm Therapeutics, Inc., and L Brands, Inc. Stockholders have until the deadlines...
Aug 05, 2019 06:48 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....
Aug 05, 2019 06:04 pm ET
CLASS ACTION UPDATE for RMED, OMCL, KPTI and CURLF: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Aug 05, 2019 02:35 pm ET
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Karyopharm Therapeutics Inc. (“Karyopharm” or “the Company”) (NASDAQ: KPTI) for violations of §§10(b) and 20(a) of the...
Aug 05, 2019 09:19 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of BOX, RLGY, KPTI and CARB
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Aug 02, 2019 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN)Class Period: 3/2/2015 - 7/17/2019Lead Plaintiff Motion Deadline: September...
Aug 02, 2019 06:08 pm ET
ROSEN, A HIGHLY RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Karyopharm Therapeutics Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm - KPT
NEW YORK, Aug. 2, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) from March 2, 2017 through February 22, 2019, inclusive (the "Class Period"). The lawsuit seeks to recover damages for Karyopharm investors under the federal securities laws....
Aug 02, 2019 04:18 pm ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Karyopharm Therapeutics, Inc.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 23, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Karyopharm Therapeutics, Inc. (“Karyopharm” or the “Company”) (NASDAQ:
Aug 02, 2019 03:00 pm ET
SHAREHOLDER ALERT - Karyopharm Therapeutics Inc. (KPTI) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Plaintiff Deadline: September 23, 2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Karyopharm Therapeutics Inc. (“Karyopharm”  or “the Company”) (NASDAQ:  KPTI) and certain of its officers, on behalf of...
Aug 02, 2019 02:54 pm ET
LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors to Contact the Firm
SAN DIEGO, Aug. 2, 2019 /PRNewswire/ -- Johnson Fistel, LLP announces that class action lawsuits have been commenced on behalf of shareholders of the publicly-traded companies listed below. The Private Securities Litigation Reform Act of 1995 permits any investor who purchased a common stock during the Class Period to seek appointment as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation.  The lead plaintiff can select a law firm of its choice.  An investor's ability to share in any potential future recovery is not dependent upon serving as...
Aug 02, 2019 11:01 am ET
CLASS ACTION UPDATE for VNTR, MMM and KPTI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Aug 02, 2019 09:21 am ET
Pawar Law Group Reminds Investors of Deadline in Securities Class Action Lawsuit Against  Karyopharm Therapeutics Inc. – KPTI
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) from March 2, 2017 through February 22, 2019, inclusive (the “Class Period”). The...
Aug 01, 2019 07:55 pm ET
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Karyopharm Therapeutics, Inc.
Law Offices of Howard G. Smith reminds investors of the upcoming September 23, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Karyopharm Therapeutics, Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI) investors that: (1) purchased shares of Karyopharm’s common stock between March 2, 2017 and Febr
Aug 01, 2019 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 67,500 shares of Karyopharm’s...
Aug 01, 2019 12:37 pm ET
CLASS ACTION UPDATE for EROS, OMCL, KPTI and JE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Aug 01, 2019 11:27 am ET
KPTI CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to file a Motion for Lead Plaintiff in a Securities Class Action Lawsuit Against Karyopharm Therapeutics Inc.
Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ: KPTI) from March 2, 2017,...
Jul 31, 2019 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN) Class Period: 3/2/2015...
Jul 31, 2019 05:45 pm ET
Rosen, a Leading Law Firm, Announces Filing of Securities Class Action Lawsuit Against Karyopharm Therapeutics Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm – KPTI
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) from March 2, 2017 through February 22, 2019, inclusive (the...
Jul 31, 2019 02:55 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....
Jul 31, 2019 09:08 am ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of RMED, CTST, OMCL and KPTI
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Jul 30, 2019 07:00 am ET
Karyopharm to Report Second Quarter 2019 Financial Results on August 6, 2019
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, announced today that it will report second quarter 2019 financial results on Tuesday, August 6, 2019. Karyopharm's management team will host a conference call...
Jul 29, 2019 04:18 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI) of the September 23, 2019 deadline to seek the role of lead plaintiff in a federal...
Jul 29, 2019 12:52 pm ET
Rosen, a Top Ranked Law Firm, Announces Filing of Securities Class Action Lawsuit Against Karyopharm Therapeutics Inc.
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) from March 2, 2017 through February 22, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Karyopharm investors under the federal securities laws.
Jul 29, 2019 09:43 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Karyopharm Therapeutics Inc. (“Karyopharm” or “the Company”) (NASDAQ: KPTI) for violations of §§10(b) and 20(a) of the...
Jul 29, 2019 09:09 am ET
SHAREHOLDER ALERT: MBNKF RLGY FRED KPTI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jul 26, 2019 10:54 pm ET
KARYOPHARM SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against
NEW ORLEANS, July 26, 2019 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 23, 2019 to file lead plaintiff applications in a securities class action lawsuit against Karyopharm Therapeutics Inc. (NasdaqGS: KPTI), if they purchased the Company's shares issued in connection with its April 2017 or May 2018 public offering or between March 2, 2017 and February 22, 2019, inclusive (the "Class Period").  This action is pending in the United States District Court for the Di...
Jul 26, 2019 07:00 pm ET
Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Karyopharm Therapeutics, Inc. Investors
Glancy Prongay & Murray LLP (“GPM”), a national investors rights law firm, announces that a class action lawsuit has been filed on behalf of Karyopharm Therapeutics, Inc. (“Karyopharm” or the “Company”) (NASDAQ:
Jul 26, 2019 04:39 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Karyopharm Therapeutics, Inc. Investors (KPTI)
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of Karyopharm Therapeutics, Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI) investors that: (1) purchased shares of Karyopharm’s common stock between March 2, 2017 and February 22, 2019, inclusive (the “Class Period”); (2) purchased Karyopharm share
Jul 26, 2019 03:00 pm ET
SHAREHOLDER ALERT - Karyopharm Therapeutics Inc. (KPTI) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Plaintiff Deadline: September 23, 2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Karyopharm Therapeutics Inc. (“Karyopharm” or “the Company”) (NASDAQ: KPTI) and certain of its officers, on behalf of...
Jul 26, 2019 02:44 pm ET
Robbins Arroyo LLP: Karyopharm Therapeutics Inc. (KPTI) Misled Shareholders According to a Recently Filed Lawsuit
Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between March 2, 2017 and February 22, 2019, and the Securities Exchange Act of 1933 for conduct related to the com
Jul 26, 2019 01:55 pm ET
CLASS ACTION UPDATE for BUD, OMCL, KPTI and NGHC: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Jul 26, 2019 01:14 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm
NEW YORK, July 26, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ: KPTI) of the September 23, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. ...
Jul 26, 2019 10:16 am ET
IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Conta
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Karyopharm Therapeutics Inc. (“Karyopharm” or “the Company”) (NASDAQ:
Jul 26, 2019 09:40 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ASNA, RLGY, LB and KPTI
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jul 25, 2019 11:07 pm ET
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Karyopharm Therapeutics Inc. (“Karyopharm” or “the Company”) (NASDAQ:
Jul 25, 2019 09:30 pm ET
Glancy Prongay & Murray LLP Announces Investigation on Behalf of Karyopharm Therapeutics, Inc. Investors (KPTI)
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Karyopharm Therapeutics, Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI) investors concerning the Company and its officers’ possible violations of federal securities laws.
Jul 25, 2019 06:53 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Karyopharm Therapeutics, Inc. Investors (KPTI)
Law Offices of Howard G. Smith announces an investigation on behalf of Karyopharm Therapeutics, Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI) investors concerning the Company and its officers’ possible violations of federal securities laws.
Jul 25, 2019 10:22 am ET
CLASS ACTION UPDATE for TUSK, BOX, PYX and KPTI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Jul 25, 2019 10:12 am ET
Karyopharm Therapeutics Shareholder Alert: Kehoe Law Firm, P.C. Investigating Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
Kehoe Law Firm, P.C. announces that it is investigating securities claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI) to determine whether Karyopharm and certain of its officers or directors...
Jul 24, 2019 11:03 pm ET
KPTI INVESTOR ALERT: Hagens Berman Alerts Investors in Karyopharm Therapeutics (KPTI) Public Offerings to Possible Disclosure Violations
SAN FRANCISCO, July 24, 2019 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Karyopharm Therapeutics Inc.'s (NASDAQ: KPTI) April 28, 2017 and May 7, 2018 public offerings to the firm's investigation into possible securities law violations....
Jul 24, 2019 09:30 pm ET
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Karyopharm Therapeutics, Inc. (NASDAQ: KPTI) and Encourages Karyopharm Investors to Contact the Firm
Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all investors that purchased Karyopharm, Inc. (NASDAQ: KPTI) securities between...
Jul 24, 2019 08:00 pm ET
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Karyopharm Therapeutics Inc. (KPTI)
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (Nasdaq: KPTI) in the United States District Court for the District of Massachusetts on behalf of...
Jul 24, 2019 01:40 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....
Jul 24, 2019 01:12 pm ET
KPTI CLASS ACTION ALERT: Bernstein Liebhard LLP Announces That a Securities Class Action Lawsuit has Been Filed Against Karyopharm Therapeutics Inc.
NEW YORK, July 24, 2019 /PRNewswire/ -- Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ: KPTI) from March 2, 2017, through February 22, 2019 (the "Class Period"). The lawsuit, filed in the United States District Court for the District of Massachusetts, seeks to recover Karyopharm shareholders' investment losses under the Securities Act of 1933 and the Securities Exchange Act of 1934....
Jul 23, 2019 06:52 pm ET
Bernstein Litowitz Berger & Grossmann LLP Announces Securities Class Action Suit Filed Against Karyopharm Therapeutics Inc. And Certain Of Its Senior Executives, Its Board Of Directors, And Underwrite
NEW YORK, July 23, 2019 /PRNewswire/ -- Bernstein Litowitz Berger & Grossmann LLP ("BLB&G") today announced that it filed a securities class action lawsuit on behalf of its client Allegheny County Employees' Retirement System ("ACERS") against Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ: KPTI), and certain of the Company's senior executives, Karyopharm's Board of Directors, and the underwriters of the Offerings, (collectively, "Defendants").  The action, which is captioned Allegheny County Employees' Retirement System v. Karyopharm Therapeutics Inc., No. 1:19...
Jul 05, 2019 09:31 am ET
Thinking about buying stock in Aurora Cannabis, Beyond Meat, Karyopharm Therapeutics, Northstar Realty, or Tyme Technologies?
NEW YORK, July 5, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, BYND, KPTI, NRE, and TYME....
Jul 03, 2019 01:06 pm ET
Karyopharm Announces FDA Approval of XPOVIO™ (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved oral XPOVIOTM (selinexor), a nuclear export inhibitor, in combination with...
Jun 28, 2019 04:37 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 55,500 shares of Karyopharm’s...
Jun 19, 2019 11:05 am ET
Karyopharm Reports Updated Data from the Phase 2b SADAL Study at the 2019 International Conference on Malignant Lymphoma
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported updated results from the Phase 2b SADAL (Selinexor Against Diffuse Aggressive Lymphoma) study evaluating selinexor, the Company’s first-in-class,...
Jun 14, 2019 07:00 am ET
 Karyopharm Reports New and Updated Selinexor Combination Data from the Phase 1b/2 STOMP Study at the European Hematology Association 2019 Annual Meeting
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced three presentations highlighting new and updated data from the Phase 1b/2 STOMP (Selinexor and Backbone Treatments of Multiple Myeloma Patients)...
Jun 03, 2019 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 95,500 shares of Karyopharm’s...
May 28, 2019 07:00 am ET
Karyopharm to Participate in Upcoming Investor Conferences
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that the Company’s management team will participate in the following upcoming investor conferences:  The Jefferies 2019 Global Healthcare...
May 16, 2019 11:06 am ET
Karyopharm Announces Results of Clinical Studies Investigating Selinexor to be Presented at the European Hematology Association 2019 Annual Meeting
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that five abstracts relating to selinexor, the Company’s first in class, oral SINE compound, will be presented at the upcoming European Hematology...
May 15, 2019 07:00 am ET
Karyopharm’s Founder Sharon Shacham, PhD, Receives NYIPLA Inventor of the Year Award
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, congratulates its founder, President and Chief Scientific Officer, Sharon Shacham, PhD, MBA, for winning the esteemed New York Intellectual Property Law...
May 09, 2019 07:02 am ET
Karyopharm Reports First Quarter 2019 Financial Results and Highlights Recent Company Progress
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the first quarter 2019 and provided an overview of recent accomplishments and clinical development progress for its innovative...
May 08, 2019 07:00 am ET
Karyopharm to Participate in Upcoming Investor Conferences
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that the Company’s management team will participate in the following upcoming investor conferences:  The Bank of America Merrill Lynch Health Care...
May 02, 2019 07:00 am ET
Karyopharm to Report First Quarter 2019 Financial Results on May 9, 2019
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report first quarter 2019 financial results on Thursday, May 9, 2019. Karyopharm's management team will host a conference call and...
May 01, 2019 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 89,500 shares of Karyopharm’s...
Apr 10, 2019 08:35 am ET
New Research Coverage Highlights BioMarin Pharmaceutical, EnLink Midstream, GCI Liberty, Vistra Energy, BioTime, and Karyopharm Therapeutics — Consolidated Revenues, Company Growth, and Expectations f
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), EnLink Midstream, LLC (NYSE:ENLC),...
Apr 01, 2019 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 38,000 shares of Karyopharm’s...
Mar 14, 2019 04:57 pm ET
Karyopharm Announces FDA Extension of Review Period for Selinexor New Drug Application
NEWTON, Mass., March 14, 2019 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) action date for the New Drug Application (NDA) for selinexor. The NDA, which is currently under Priority Review by the FDA, is seeking accelerated approval for selinexor in combination with dexamethasone for the treatment of patients with relapsed refractory multiple myeloma who have received at least three prior therapies and whose disease is...
Feb 28, 2019 04:51 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that it has granted stock options to Michael P. Mason, the Company’s newly-appointed Senior Vice President, Chief Financial Officer and Treasurer,...
Feb 28, 2019 07:00 am ET
Karyopharm Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the fourth quarter and full year 2018 and provided a business update and an overview of recent accomplishments for selinexor,...
Feb 26, 2019 05:47 pm ET
Karyopharm Announces Outcome of FDA Advisory Committee Meeting Reviewing Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) met to discuss the New Drug Application (NDA) for...
Feb 26, 2019 12:31 pm ET
Karyopharm Stock Trading Halted Today; FDA Advisory Committee Meeting to Discuss Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma Who Have Received At Least Three
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that NASDAQ has halting trading of the Company’s common stock. The U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee...
Feb 25, 2019 07:00 am ET
Karyopharm Strengthens Management Team with Appointment of Michael P. Mason as Chief Financial Officer
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of Michael P. Mason as Senior Vice President, Chief Financial Officer and Treasurer. In this role, Mr. Mason will be responsible...
Feb 21, 2019 07:35 am ET
Research Report Identifies Johnson & Johnson, Schlumberger, Karyopharm Therapeutics, WYNDHAM DESTINATIONS, INC, ASGN, and Suburban Propane Partners with Renewed Outlook — Fundamental Analysis, Calcula
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Johnson & Johnson (NYSE:JNJ), Schlumberger Limited (NYSE:SLB), Karyopharm...
Feb 21, 2019 07:00 am ET
Karyopharm to Report Fourth Quarter and Full Year 2018 Financial Results on February 28, 2019
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report fourth quarter and full year 2018 financial results on Thursday, February 28, 2019. Karyopharm's management team will host a...
Feb 07, 2019 07:00 am ET
Karyopharm Announces FDA Advisory Committee Meeting to Review Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma Who Have Received At Least Three Prior Therapies
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) is scheduled to review data supporting the...
Feb 04, 2019 07:00 am ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 428,500 shares of...
Jan 08, 2019 12:20 pm ET
Karyopharm Announces Submission of Marketing Authorization Application to the European Medicines Agency for Selinexor for the Treatment of Patients with Penta-Refractory Multiple Myeloma
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for selinexor, the Company’s...
Jan 02, 2019 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 78,000 shares of Karyopharm’s...
Jan 02, 2019 07:00 am ET
Karyopharm to Present at the 37th Annual J.P. Morgan Healthcare Conference
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7,...
Dec 04, 2018 07:00 am ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 180,500 shares of...
Dec 03, 2018 11:00 am ET
Karyopharm Reports Updated Selinexor Data from the Phase 2b STORM and Phase 1b/2 STOMP Studies in Relapsed/Refractory Multiple Myeloma at the American Society of Hematology 2018 Annual Meeting
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced presentations highlighting updated data from the Phase 2b STORM study evaluating selinexor, the Company’s first-in-class, oral Selective Inhibitor...
Dec 01, 2018 12:00 pm ET
Karyopharm Reports Positive Top-Line Phase 2b SADAL Data for Selinexor in Patients with Diffuse Large B-Cell Lymphoma at the American Society of Hematology 2018 Annual Meeting
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported positive top-line results from the Phase 2b SADAL (Selinexor Against Diffuse Aggressive Lymphoma) study evaluating selinexor, the Company’s...
Nov 13, 2018 08:10 am ET
Report: Developing Opportunities within Evelo Biosciences, ADMA Biologics, Karyopharm Therapeutics, Pingtan Marine Enterprise, Rosetta Stone, and Williams Companies — Future Expectations, Projections
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Evelo Biosciences, Inc. (NASDAQ:EVLO), ADMA Biologics Inc (NASDAQ:ADMA),...
Nov 08, 2018 07:00 am ET
Karyopharm Reports Third Quarter 2018 Financial Results and Highlights Recent Company Progress
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the third quarter 2018 and provided an overview of recent accomplishments for selinexor, its lead, novel, oral SINE compound,...
Nov 07, 2018 08:00 am ET
Karyopharm’s Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to selinexor, the Company’s first-in-class, oral SINE compound...
Nov 07, 2018 07:00 am ET
Karyopharm to Present at the Jefferies 2018 London Healthcare Conference
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the Jefferies 2018 London Healthcare Conference on Wednesday, November 14,...
Nov 05, 2018 07:00 am ET
Karyopharm Therapeutics to Ring Nasdaq Closing Bell on November 6th
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that company executives, including founder Sharon Shacham PhD, MBA, President and Chief Scientific Officer and cofounder Michael G. Kauffman MD,...
Nov 02, 2018 07:00 am ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 127,500 shares of...
Nov 01, 2018 10:17 am ET
Karyopharm Announces Results of Clinical Studies Investigating Selinexor in Multiple Myeloma and Diffuse Large B-Cell Lymphoma to be Presented at the American Society of Hematology 2018 Annual Meeting
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that ten abstracts have been selected for presentation, including three oral presentations, at the upcoming American Society of Hematology (ASH)...
Nov 01, 2018 07:00 am ET
Karyopharm to Report Third Quarter 2018 Financial Results on November 8, 2018
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report third quarter 2018 financial results on Thursday, November 8, 2018. Karyopharm's management team will host a conference call...
Oct 29, 2018 07:00 am ET
Karyopharm Therapeutics Announces Closing of Additional $22.5 Million of 3.00% Convertible Senior Notes Due 2025 Pursuant to Exercise in Full of Initial Purchasers’ Option
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it has issued an additional $22.5 million aggregate principal amount of its 3.00% convertible senior notes due 2025 (the “notes”) pursuant to...
Oct 26, 2018 07:00 am ET
Karyopharm Therapeutics Announces Management Change
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Mike Falvey, Executive Vice President, Chief Financial Officer and Treasurer, intends  to leave the company to pursue other interests.   Mr....
Oct 11, 2018 07:00 am ET
Karyopharm Therapeutics Announces Pricing of $150 Million of Convertible Senior Notes
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the pricing of $150 million aggregate principal amount of its 3.00% convertible senior notes due 2025 (the “Notes”).  The Notes will be sold in a...
Oct 09, 2018 04:01 pm ET
Karyopharm Therapeutics Announces Proposed Private Offering of $150 Million of Convertible Senior Notes
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it intends to offer, subject to market and other conditions, $150 million aggregate principal amount of convertible senior notes due 2025 (the...
Oct 05, 2018 05:43 pm ET
U.S. Food and Drug Administration Accepts Karyopharm’s New Drug Application for Selinexor and Grants Priority Review
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with Priority Review its New Drug Application (NDA) seeking accelerated...
Oct 01, 2018 07:00 am ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 108,900 shares of...
Sep 25, 2018 07:00 am ET
Karyopharm to Participate in Upcoming Investor Conferences
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that members of the Company’s management team will participate in the following upcoming investor conferences:  The Cantor Fitzgerald Global...
Sep 20, 2018 04:05 pm ET
Selinexor Clinical Data to be Presented at the 21st Annual Meeting of the Chinese Society of Clinical Oncology
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced two oral presentations and one poster presentation highlighting previously reported clinical data relating to selinexor, the Company’s lead, oral...
Sep 13, 2018 07:20 pm ET
Phase 2b STORM Data Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma Presented at the Society of Hematologic Oncology 2018 Annual Meeting
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that updated clinical data from the Phase 2b STORM (Selinexor Treatment of Refractory Myeloma) study evaluating selinexor, the Company’s lead, oral...
Sep 04, 2018 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 62,500 shares of Karyopharm’s...
Sep 04, 2018 07:00 am ET
Karyopharm Appoints Carsten Thiel, Ph.D., to its Board of Directors
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of Carsten Thiel, Ph.D., to its Board of Directors. Dr. Thiel is currently Chief Executive Officer of Abeona Therapeutics Inc., a...
Aug 29, 2018 07:00 am ET
Karyopharm to Participate in Upcoming Investor Conferences
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that members of the Company’s management team will participate in the following upcoming investor conferences:  The Baird 2018 Global Healthcare...
Aug 28, 2018 06:22 pm ET
Karyopharm to Present Phase 2b STORM Data Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma at the Society of Hematologic Oncology 2018 Annual Meeting
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that clinical data from the Phase 2b STORM study evaluating the Company’s lead, oral Selective Inhibitor of Nuclear Export (SINE) compound...
Aug 17, 2018 07:45 am ET
Report: Developing Opportunities within FORTERRA INC, Baytex Energy, MAG Silver, Bojangles', Ciner Resources LP, and Karyopharm Therapeutics — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of FORTERRA INC (NASDAQ:FRTA), Baytex Energy Corp (NYSE:BTE), MAG Silver...
Aug 07, 2018 07:00 am ET
Karyopharm Reports Second Quarter 2018 Financial Results and Highlights Recent Progress
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the second quarter 2018 and provided an overview of recent accomplishments and clinical development plans for selinexor, its...
Aug 06, 2018 04:05 pm ET
Karyopharm Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Selinexor as a Treatment for Patients with Penta-Refractory Multiple Myeloma
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the completion of the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated...
Aug 03, 2018 07:00 am ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 196,500 shares of Karyopharm’s...
Aug 02, 2018 07:00 am ET
Karyopharm to Participate in Upcoming Investor Conferences
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that members of the Company’s management team will participate in the following upcoming investor conferences:  The Canaccord Genuity 38th Annual...
Jul 31, 2018 07:00 am ET
Karyopharm to Report Second Quarter 2018 Financial Results on August 7, 2018
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report second quarter 2018 financial results on Tuesday, August 7, 2018. Karyopharm's management team will host a conference call and...
Jul 25, 2018 04:05 pm ET
Karyopharm Appoints Ian Karp as Vice President, Investor and Public Relations
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of Ian Karp as Vice President, Investor and Public Relations.  In this role, Mr. Karp will lead all of the Company’s corporate...
Jul 18, 2018 07:00 am ET
Karyopharm Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Selinexor as a Treatment for Patients with Penta-Refractory Multiple Myeloma
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Company has initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking...
Jul 02, 2018 07:00 am ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 146,500 shares of Karyopharm’s...